The absence of any hantavirus vaccine candidates in late-stage Phase 3 trials as of mid-2026 drives the market's 94.5% "No" odds, reflecting standard regulatory timelines that rarely compress from early immunogenicity data to licensure in under a year. DNA and mRNA platforms targeting Gn-Gc glycoproteins have shown neutralizing antibodies in Phase 1/2 studies for strains like Hantaan, Puumala, and Andes virus, yet the disease's low incidence—primarily sporadic rodent-borne cases—complicates enrollment for efficacy trials needed to confirm protection against hantavirus pulmonary syndrome. Recent 2026 outbreaks have accelerated preclinical work and funding, but historical precedent and the absence of emergency-use pathways for this pathogen leave realistic acceleration scenarios, such as rapid pivotal data from expanded trials, improbable before year-end.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$129,623 Vol.
$129,623 Vol.
31 dez 2026
6% chance
$129,623 Vol.
$129,623 Vol.
31 dez 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidates in late-stage Phase 3 trials as of mid-2026 drives the market's 94.5% "No" odds, reflecting standard regulatory timelines that rarely compress from early immunogenicity data to licensure in under a year. DNA and mRNA platforms targeting Gn-Gc glycoproteins have shown neutralizing antibodies in Phase 1/2 studies for strains like Hantaan, Puumala, and Andes virus, yet the disease's low incidence—primarily sporadic rodent-borne cases—complicates enrollment for efficacy trials needed to confirm protection against hantavirus pulmonary syndrome. Recent 2026 outbreaks have accelerated preclinical work and funding, but historical precedent and the absence of emergency-use pathways for this pathogen leave realistic acceleration scenarios, such as rapid pivotal data from expanded trials, improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado Aberto: May 4, 2026, 10:39 AM ET
Volume
$129,623Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidates in late-stage Phase 3 trials as of mid-2026 drives the market's 94.5% "No" odds, reflecting standard regulatory timelines that rarely compress from early immunogenicity data to licensure in under a year. DNA and mRNA platforms targeting Gn-Gc glycoproteins have shown neutralizing antibodies in Phase 1/2 studies for strains like Hantaan, Puumala, and Andes virus, yet the disease's low incidence—primarily sporadic rodent-borne cases—complicates enrollment for efficacy trials needed to confirm protection against hantavirus pulmonary syndrome. Recent 2026 outbreaks have accelerated preclinical work and funding, but historical precedent and the absence of emergency-use pathways for this pathogen leave realistic acceleration scenarios, such as rapid pivotal data from expanded trials, improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$129,623Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The absence of any hantavirus vaccine candidates in late-stage Phase 3 trials as of mid-2026 drives the market's 94.5% "No" odds, reflecting standard regulatory timelines that rarely compress from early immunogenicity data to licensure in under a year. DNA and mRNA platforms targeting Gn-Gc glycoproteins have shown neutralizing antibodies in Phase 1/2 studies for strains like Hantaan, Puumala, and Andes virus, yet the disease's low incidence—primarily sporadic rodent-borne cases—complicates enrollment for efficacy trials needed to confirm protection against hantavirus pulmonary syndrome. Recent 2026 outbreaks have accelerated preclinical work and funding, but historical precedent and the absence of emergency-use pathways for this pathogen leave realistic acceleration scenarios, such as rapid pivotal data from expanded trials, improbable before year-end.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions